Pathos Expands Pipeline With Worldwide License of Ph 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor August 22, 2024
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical August 13, 2024
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers August 13, 2024
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines August 13, 2024
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai to Discover and Develop Novel Molecular Glue Degraders for Oncology Indications August 13, 2024
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 August 13, 2024
IDEAYA Biosciences Announces Option and License Agreement for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen August 7, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
Boehringer Ingelheim secures novel immune checkpoint inhibitors with acquisition of Nerio Therapeutics August 7, 2024
Vir Biotechnology gets in Exclusive Worldwide License Agreement with Sanofi for Multiple Clinical-Stage T-cell Engagers August 7, 2024
Immunome acquired worldwide, exclusive rights to a panel of antibodies from Nectin Therapeutics, Bluefin Biomedicine, and from OncoResponse July 30, 2024
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production July 30, 2024
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline July 23, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations for Evaluating ORIC-944 + AR Inhibitors for the Treatment of Prostate Cancer July 23, 2024
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
CatalYm Announces New Financing of $150M to Support Broad Ph 2b Development Program for Visugromab July 23, 2024
